Guardian molecule keeps cells on track: New perspectives for the treatment of liver cancer
A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the ...
Active agent against cancer metastasis discovered: Adhibin prevents migration and attachment to other cells
Every cell in the body normally has its fixed place as part of a tissue structure. Except for a few cell types, such as blood ...
EurekAlert!2d
Utilizing a nanomedicine to achieve tumor catalysis-enhanced differentiation therapy
In a paper published in National Science Review, an international team of scientists report a coordination nanomedicine ...
Mirage News2d
Guardian Molecule Paves New Path in Liver Cancer Care
A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the ...
News Medical on MSN3d
New immune map uncovers key pancreatic cancer insights
Researchers determine a complex immune infiltrate pattern based on a newly constructed immune map developed using pancreatic ...
The Brighterside of News on MSN5d
Breakthrough new treatment could stop cancer from reaching the brain
Brain metastases (BMs) are a devastating complication of cancer, occurring ten times more frequently than primary brain ...
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented ...
GlobalData on MSN4d
BMS’ Phase II trial of CAR T cell therapy meets primary endpoint
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
Business Insider12d
Salarius announces patient enrollment to resume for trial on seclidemstat
Inhibiting LSD1 in preclinical in vivo hematologic models has previously demonstrated reprogramed cancer cell differentiation, reduced tumor burden and prolonged survival of treated animals studied.
Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.